Physician profile
Daphne Jones
NPI 1881675965
$1,298.03
in general payments reported to CMS, 2019-2025
26 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $87.51 · 2021: $271 · 2022: $279 · 2023: $211 · 2024: $96.38 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $257.54 | 2019-2023 | |
| Novo Nordisk INC | $219.48 | 2020-2024 | Wegovy |
| Hologic Sales and Service, LLC | $125.94 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Coolseal Generator |
| Astellas Pharma US INC | $97.38 | 2019-2025 | Veozah, Myrbetriq |
| Bausch Health US, LLC | $73.37 | 2019-2022 | |
| Pfizer INC. | $66.63 | 2019-2023 | |
| Aspira Women'S Health INC | $53.91 | 2021 | |
| Sage Therapeutics, LLC | $50.13 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $36.10 | 2019-2020 | |
| Organon LLC | $33.86 | 2022-2025 | Jada System |
| Shield Therapeutics INC | $21.92 | 2024 | |
| Sumitomo Pharma America, INC. | $21.91 | 2024 | Gemtesa |
| Therapeuticsmd, INC. | $21.36 | 2019 | |
| Roche Diagnostics Corporation | $21.02 | 2019 | |
| Daiichi Sankyo INC. | $19.67 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.66 | 2025 | Qelbree |
| Mayne Pharma Commercial LLC | $18.65 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.54 | 2023 | |
| Monaghan Medical Corporation | $18.33 | 2023 | Aerobika |
| Becton, Dickinson and Company | $18.31 | 2019 | |
| Agile Therapeutics, INC. | $17.74 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.54 | 2020 | |
| Lilly USA, LLC | $14.57 | 2023 | Emgality |
| Avion Pharmaceuticals | $12.81 | 2020 | |
| Exeltis, USA INC. | $11.39 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphne Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.